Vitality Watch

Dossier pubmed observational 27-jul-2026
Human cohort, case-control, or epidemiological association

Global and regional projections of atherosclerotic cardiovascular-kidney-liver-metabolic disease burden to 2050: a forecasting analysis for the global burden of disease study 2023.

Key claim: By 2050 absolute global CKLM burden is projected to rise sharply—driven by population ageing and growth—as metabolic antecedents (T2DM, CKD, MASLD, obesity) roughly double and expand from about one-third to nearly half of total CKLM composition, despite modest declines in age-standardised atherosclerotic CVD rates.

Abstract

BACKGROUND: Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), metabolic dysfunction-associated steatotic liver disease (MASLD), and obesity coexist under the cardiovascular-kidney-liver-metabolic (CKLM) framework and account for nearly one third of global deaths, yet long-term projections of their combined burden are lacking. METHODS: Using the Global Burden of Disease 2023 study, we projected incidence, prevalence, mortality, and disability-adjusted life years (DALYs) across 204 countries from 2026 to 2050, stratified by age, sex, geography, and sociodemographic index (SDI). The CKLM burden was organised into metabolic antecedents, comprising T2DM, CKD, MASLD and obesity; and downstream atherosclerotic CVD, comprising ischaemic heart disease, stroke, aortic aneurysm, and peripheral artery disease. ARIMA was selected as the primary forecasting model following out-of-sample validation of five candidate time-series models. Risk-deleted analyses estimated burden reduction achievable through elimination of modifiable risk factors. RESULTS: By 2050, the global CKLM burden is projected to affect 4.7 billion (95%UI: 4.4 to 5.0 billion) aggregate prevalent condition counts, with 220.6 million incident cases (95%UI: 208.9 to 232.3 million), contributing 860.1 million DALYs and 32.4 million deaths. Crude DALYs are projected to rise 52.1% (95%UI: 23.6 to 80.7) from 2026 to 2050, driven by a 25.8% (95%UI: 10.7 to 40.8) rise in atherosclerotic CVD and a doubling of metabolic antecedents (100.0%; 95%UI: 14.9 to 185.0). Age-standardised DALY rates are anticipated to fall 14.9% (95%UI: -37.4 to 7.5), with a 31.4% (95%UI: -45.8 to -16.9) reduction in atherosclerotic CVD offset by a 14.6% (95%UI: -47.4 to 76.6) rise in metabolic antecedents. Metabolic antecedents are projected to expand from 35.7% to 48.1% of total CKLM burden between 2026 and 2050. CKLM burden is highest and fastest-growing in low-middle SDI regions and South Asia. Risk-deleted analyses identify high fasting plasma glucose (39.4% reduction), high systolic blood pressure (34.4% reduction), and dietary risks (28.1% reduction) as the highest-yield modifiable targets. INTERPRETATION: By 2050, modest improvements in age-standardised cardiovascular-kidney-liver-metabolic morbidity will be overwhelmed by a substantial rise in absolute burden driven by population ageing and growth, as upstream metabolic antecedents expand from one-third to nearly half of the total CKLM composition.

Why this matters

Nutrition and metabolic interventions in this area are usually evaluated against individual-level surrogate endpoints; a GBD long-horizon forecast reframes them against the absolute population burden they are implicitly meant to blunt. The projection that metabolic antecedents (obesity, T2DM, MASLD, CKD) roughly double and overtake atherosclerotic CVD as the dominant CKLM component by 2050 shifts the composition of what dietary and fasting strategies would need to address, even though age-standardised atherosclerotic rates are modestly falling. It is a demographic synthesis, not a mechanistic or trial result, and does not change the evidence tier of any specific intervention on these pages.

Source

Link

Briefing card

Global and regional projections of atherosclerotic cardiovascular-kidney-liver-metabolic disease burden to 2050: a forecasting analysis for the global burden of disease study 2023.
Stage: observational · pubmed · 27-jul-2026

If you follow nutrition and metabolic-aging research, this forecast says the disease mix those interventions target is shifting toward metabolic-antecedent conditions (diabetes, CKD, fatty liver, obesity) rather than classical atherosclerotic CVD by 2050.

By 2050 absolute global CKLM burden is projected to rise sharply—driven by population ageing and growth—as metabolic antecedents (T2DM, CKD, MASLD, obesity) roughly double and expand from about one-third to nearly half of total CKLM composition, despite modest declines in age-standardised atherosclerotic CVD rates.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.metabol.2026.156716

build build 880 · 2bcef25 · 2026-11-18